Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
Conditions
- Metastatic Urothelial Carcinoma
- Unresectable Urothelial Carcinoma
- Advanced Urothelial Carcinoma
Interventions
- DRUG: Enfortumab vedotin
- DRUG: Pembrolizumab
Sponsor
Fox Chase Cancer Center
Collaborators